Core Viewpoint - Genmab has made significant progress in its late-stage programs, particularly with three key assets that have received FDA breakthrough therapy designations, indicating strong potential for future growth and product launches [2]. Group 1: Company Progress - Genmab's late-stage programs include EPKINLEY, Rina-S, and peto, all of which have received at least one FDA breakthrough therapy designation [2]. - The company has observed significant clinical data developments in 2025 that have bolstered confidence in these programs [2]. - Looking ahead to 2026, Genmab anticipates meaningful registrational data that could lead to important product launches in 2027 [2].

Core Insights - SystImmune, Inc., a wholly-owned subsidiary of Baillie Gifford (688506.SH), has received Breakthrough Therapy Designation from the FDA for izalontamabbrengitecan (iza-bren) for treating locally advanced or metastatic non-small cell lung cancer with specific mutations after prior treatments [1][2] Group 1 - The Breakthrough Therapy Designation is based on clinical research data from studies BL-B01D1-101, BL-B01D1-203, and BL-B01D1-LUNG-101, demonstrating the reliability of existing data [2] - The designation highlights the significant unmet clinical needs faced by patients after EGFR TKI and platinum-based chemotherapy, as most patients experience disease progression approximately 18 months after first-line treatment [2] - The FDA's Breakthrough Therapy Designation aims to expedite the development and review process for drugs that may significantly outperform existing standard therapies [2]